629 results on '"Tsuchiya, Kaoru"'
Search Results
2. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
3. Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease
4. Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality
5. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group
6. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
7. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup
8. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
9. FRI-026 Longitudinal association of magnetic resonance elastography with liver-related events and cardiovascular events in chronic hepatitis
10. Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’
11. Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease
12. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
13. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease.
14. Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B
15. Impact of immune‐related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
16. Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
17. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
18. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study.
19. Enhanced Liver Fibrosis Score for Diagnosing Liver Fibrosis in Chronic Hepatitis.
20. Concordance between metabolic dysfunction‐associated steatotic liver disease and nonalcoholic fatty liver disease.
21. Heightened risk of early vocal fold motion impairment onset and dysphagia in the parkinsonian variant of multiple system atrophy: a comparative study
22. Clinical impact on treatment effectiveness of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
23. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
24. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
25. Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography
26. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.
27. Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population
28. Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
29. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
30. Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
31. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease
32. Analysis of disease progression in patients with chronic hepatitis B using a large nationwide database
33. The importance of regular screening for HCC in non-alcoholic steatohepatitis/non-alcoholic fatty liver disease
34. Clinical impact of relative dose intensity over the first four weeks in cabozantinib therapy for unresectable hepatocellular carcinoma
35. Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy
36. Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
37. 人流データを用いた国立公園ごとの滞在人口の把握とビジターセンターの立地特性の分析
38. Revisions of the clinical practice guidelines for hepatocellular carcinoma in 2021 version
39. Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
40. IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.
41. The impact of relative dose intensity on overall and progression-free survival during cabozantinib therapy for unresectable hepatocellular carcinoma.
42. Clinical utility of comprehensive genomic profiling in patients with unresectable primary liver cancer.
43. Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease
44. Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy
45. Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma
46. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study
47. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
48. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease
49. Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease
50. L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.